Hematology: Clinical Studies Open For Enrollment
Allogeneic Stem Cell Transplant to Induce Mixed Donor Chimerism in Patients with Sickle Cell Disease & Thalassemia NYMC 556
Eligibility
- Subject is 30 years of age or younger
- Diagnosis of Homozygous Hemoglobin S Disease or Heterozygous Hemoglobin Sickle Cell (SC) or S 0/+ thalassemia, or Sickle/variant resulting in Chronic Hemolytic Anemia with hemoglobin (HgB) less than or equal to 10 mg/dL
Enrollment Status: Enrolling
Study Information
ClinicalTrials.gov | NCT00408447
Principal Investigator
Mitchell S. Cairo, MD
Contact for Study Screening
Lauren_Harrison@nymc.edu
A prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders
Enrollment Status: Enrolling
Study Information
ClinicalTrials.gov | NCT01186913
Principal Investigator
Jordan Brittni Milner, MD
Contact for Study Screening
Lauren_Harrison@nymc.edu
The use of dose dense rituximab for high risk patients with newly diagnosed acute immune thrombocytopenic purpura
Enrollment Status: Enrolling
Principal Investigator
Jordan Brittni Milner, MD
Contact for Study Screening
Lauren_Harrison@nymc.edu
A Pilot Study to Determine the Safety of Defibrotide in Children with High Risk Kawasaki Disease (NYMC-204)
Eligibility
- Subject is 11 years of age or younger
- Kawasaki disease presumptive diagnosis and initiation of defibrotide within 96 hours from the conclusion of IVIG treatment
Enrollment Status: Enrolling
Study Information
ClinicalTrials.gov | NCT04323748
Principal Investigator
Mitchell S. Cairo, MD
Contact for Study Screening
Lauren_Harrison@nymc.edu
NYMC-598, A Phase II Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogeneic Hematopoietic Cell Transplantation in Children, Adolescents and Young Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (T ALL/T LLy) (ALLO-T-DART) (NCT04972942)
Eligibility
- Age: less than or equal to 39 years
- Diagnosis: T-cell acute lymphoblastic leukemia in second or subsequent remission (less than or equal to 5% blasts).
- Relapsed T-cell lymphoblastic lymphoma with complete response after reduction therapy.
- Donor Status: Planned allogeneic stem cell transplantation with donor identified.
Enrollment Status: Enrolling
Study Information
ClinicalTrials.gov | NCT04972942
Principal Investigator
Mitchell S. Cairo, MD
Contact for Study Screening
Lauren_Harrison@nymc.edu
Eligibility
- Male or Female Age ≤ 25 years
- An available related HLA-haploidentical donor that is determined to be the most appropriate donor for the patient by the treating physician
- AML in CR1 (defined as <5% blasts in BM by morphology and flow cytometry) having at least one of these high-risk features
- Recovery from prior cycle of chemotherapy as defined by an absolute neutrophil count ≥ 500/mm3
- AML secondary to select germline marrow failure disorders (with exception of Fanconi Anemia) may be eligible but require approval from Protocol Chairs prior to enrollment
- Exclusion Criteria: for matched healthy controls; Active extramedullary disease, Unresolved/ongoing and serious viral, bacterial, or fungal infection despite appropriate treatment, Prior allogeneic transplant and Patients with Fanconi Anemia and Down syndrome
Enrollment Status: Enrolling
Study Information
ClinicalTrials.gov | NCT04836390
Principal Investigator
Aliza Gardenswartz, MD
Contact for Study Screening
Lauren_Harrison@nymc.edu